Categories

Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business

Popular Articles

3i Infotech erases gains, ends down 2%
The stock erased all its gains and slipped into the negative terrain to touch a low of Rs 90. The scrip finally ended at Rs 91, down 2% from its previous close. The counter clocked volumes of 3.71 million shares as compared to the two-week daily average traded volumes of 1.11 million shares on the BSE.

payday loans online
AES officials to hold talks with Orissa government on IB expansion
Two senior officials of AES Corporation are likely to visit Orissa on 17 November to hold discussion with the government officials pertaining to the proposed expansion of the unit-3 & 4 (660Mw x 2) of the IB Thermal Power Station of the Orissa Power Generation Corporation (OPGC).

News of the day

Cong MP escapes from hospital; police searching for him
Police are on the lookout for Congress MP L Rajagopal, who escaped from a city hospital where he was admitted after being brought from a hunger strike site over the Telangana issue.
International Business

Bharat Biotech secures patent for Lysostaphin

Hyderabad-based vaccines and biotherapeutics manufacturer Bharat Biotech International said on Wednesday that its anti-staphylococcal molecule Lysostaphin had secured patent rights in US, Europe, China, Australia and other nations. - Bharat Biotech gets patent for Lysostaphin - Bharat Biotech to test swine flu vaccine in 2 months - Bharat Biotech to set up Rs 100 cr animal vaccine unit - Bharat Bio launches first indigenous single-shot against 5 diseases - Bharat Bio launches first indigenous single-shot against 5 diseases Lysostaphin is a potent anti-staphylococcal therapeutic with a targeted specificity against staphylococcus aureus, which causes a range of diseases including wound infections, systemic and life-threatening conditions (endocarditis), osteomyelitis, pneumonia, brain abscesses, meningitis and bacteremia, food poisoning, scalded skin syndrome and toxic shock syndrome. Krishna Ella, chairman and managing director, said the patent rights for lysostaphin was a significant milestone in the company’s new therapeutic product development programme and would pave the way to develop products for regulated markets in addition to India. A pre-investigational new drug (IND) application meeting of the pre-clinical data has already been held with US FDA, he said. Lysostaphin is bactericidal and is indifferent to antibiotic resistance. This is the first biotech product molecule patent by an Indian company.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009